Gilead Sciences, Inc. vs Visa Inc.: Strategic Comparison

This in-depth comparison examines Gilead Sciences, Inc. and Visa Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Gilead Sciences, Inc. on its own, evaluating Visa Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Gilead Sciences, Inc. and Visa Inc. is widest.

On the headline numbers, Gilead Sciences, Inc. reports annual revenue of $29.4B against $40.0B for Visa Inc., while their respective market capitalizations stand at $161.8B and $729.4B. Gilead Sciences, Inc. is headquartered in United States and Visa Inc. operates from United States, and those different home markets shape how each company competes.

Gilead Sciences, Inc.: The financial mechanics of this diversified model are exceptionally complex, requiring the simultaneous management of a high-volume, high-margin small molecule manufacturing network for HIV therapies, and a highly customized, logistically complex autologous cell therapy supply chain for oncology. This margin structure is vastly superior to the 15-20% margins typical of generic manufacturers, but it requires massive upfront capital deployment in specialized manufacturing facilities and clinical development programs. The revenue streams are heavily concentrated in a few massive blockbuster franchises. The antibody-drug conjugate (ADC) model used by Trodelvy involves attaching a highly potent cytotoxic payload, specifically SN-38, to a monoclonal antibody that targets the Trop-2 receptor expressed on the surface of cancer cells. The CAR-T cell therapy model used by Yescarta represents a fundamentally different economic model, requiring the extraction of a patient's own T cells, their genetic modification using a lentiviral vector to express a chimeric antigen receptor, and their reinfusion into the patient after a complex manufacturing process that takes approximately three weeks. The commercial infrastructure required to support this model is highly specialized. Gilead employs a sales force of thousands of highly trained scientific liaisons who engage directly with infectious disease specialists, oncologists, and hematologists, providing complex clinical data rather than simple product pitches. In the oncology space, the competitive dynamics are far more complex. Companies like Regeneron in oncology and Vertex in rare diseases operate with lower overhead and higher R&D efficiency, allowing them to bring novel modalities to market faster than a diversified giant like Gilead. This high gross margin is characteristic of the innovative biopharmaceutical industry and reflects the relatively low marginal cost of manufacturing small molecule drugs and biologics once the initial capital-intensive manufacturing facilities have been built and the regulatory approvals have been obtained. The discontinuation of magrolimab in 2023 following Phase III trial failures in myelodysplastic syndromes resulted in a significant write-down and highlighted the unforgiving nature of late-stage clinical development.

Visa Inc.: Visa is a payments infrastructure company with consumer-brand visibility. The card logo is only the surface. Underneath it sits a high-margin network that monetizes authorization, clearing, settlement, fraud control, tokenization, rules, and global acceptance.

Gilead Sciences, Inc. and Visa Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Gilead Sciences, Inc. and Visa Inc..

Gilead Sciences, Inc. business model: Gilead makes money by discovering, developing, manufacturing, and commercializing patented medicines, with FY2025 revenue led by HIV therapies and supported by liver-disease, oncology, cell-therapy, and royalty/contract revenue. The HIV franchise generated $20.8 billion in product sales in 2025, led by Biktarvy at $14.3 billion, while Veklury continued to decline as COVID-19 hospitalizations normalized. The model depends on patent-protected pricing, clinical evidence, global market access, manufacturing reliability, and pipeline renewal through internal R&D and acquisitions.

Visa Inc. business model: Visa makes money from service revenues tied to payments volume, data processing revenues tied to transactions, international transaction revenues, and value-added services such as fraud prevention, consulting, tokenization, identity, dispute tools, and Visa Direct. The company does not usually lend to cardholders. That matters because Visa avoids the balance-sheet credit risk that banks carry while still earning fees when transactions flow across its network. The more credentials, merchants, issuers, acquirers, wallets, and platforms connected to Visa, the stronger the network becomes.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Gilead Sciences, Inc. stack up against those of Visa Inc..

Gilead Sciences, Inc. competitive advantage: The execution of this strategy requires flawless commercial execution and unprecedented manufacturing scale, capabilities that were severely tested during the rapid scale-up of Yescarta production and the global deployment of Veklury. This franchise relies on the continuous optimization of single-tablet regimens that combine multiple antiretroviral agents, such as bictegravir, emtricitabine, and tenofovir alafenamide, into a single pill that patients can take once daily with a high genetic barrier to resistance. This targeted delivery mechanism allows for the destruction of tumor cells while minimizing systemic toxicity, a clinical advantage that has driven rapid adoption in third-line triple-negative breast cancer and second-line urothelial cancer. The CAR-T market is particularly vicious because patient switching costs are high, and physicians are reluctant to change therapies unless new data demonstrates superior long-term outcomes and a better safety profile. This dynamic creates a constant tension between internal R&D productivity and external capital deployment, a balance that CEO Daniel P. O'Day has managed by strictly prioritizing acquisitions that offer late-stage, de-risked assets in areas where Gilead already has commercial scale. The successful completion of these trials has established lenacapavir as a significant prevention agent, a competitive advantage that is extremely difficult for new entrants to replicate without conducting their own multi-year, multi-billion dollar outcomes trials. The scale-up of Yescarta production requires the continuous addition of new clean room suites and the optimization of the lentiviral vector supply chain, a logistical challenge that exposes the company to production delays, regulatory inspections, and raw material shortages. The bictegravir molecule, the integrase strand transfer inhibitor at the core of Biktarvy, is not a simple chemical entity that can be easily reverse-engineered by generic manufacturers; it requires a highly complex synthetic pathway and precise formulation to achieve the optimal pharmacokinetic profile that allows for once-daily dosing with a high genetic barrier to resistance. This specific molecular architecture is protected by a dense thicket of composition-of-matter, formulation, and method-of-use patents that do not expire until the 2030s, creating a legal barrier to entry that is virtually impossible to close quickly. The clinical data package surrounding Biktarvy, encompassing over 100,000 patient-years of exposure across the GS-US-380-1474, GS-US-380-1489, and GS-US-380-4030 trial programs, represents a competitive advantage that is rooted in deep scientific expertise, massive capital barriers, and regulatory exclusivity. The transition to lenacapavir, a first-in-class capsid inhibitor, further solidifies this competitive advantage. The manufacturing moat for the company's CAR-T therapies is equally formidable. Gilead operates the largest autologous CAR-T manufacturing network in the world, located in El Segundo, California, and Lingan, Belgium, which are specifically designed to handle the complex biological processes required to produce Yescarta at commercial scale. The sheer cost and regulatory complexity of building and operating these facilities deter all but the most well-capitalized competitors from attempting to enter the CAR-T space, giving Gilead a significant cost and scale advantage that will be difficult to replicate. This regulatory expertise, combined with its manufacturing scale and clinical data dominance, creates a comprehensive competitive advantage that positions Gilead as the undisputed leader in the rapidly evolving field of oncology cell therapies. The commercial infrastructure required to support this advantage is equally specialized. The early data has shown promising tumor response rates and safety profiles, suggesting that Gilead could potentially launch the first next-generation ADC in these indications by 2028, establishing another first-mover advantage in a completely new therapeutic area and creating a multi-billion dollar revenue stream that would significantly diversify the company's oncology portfolio. The successful commercialization of these advanced modalities will require the development of new manufacturing capabilities and commercial infrastructure, as allogeneic therapies are typically administered as a single dose and require complex, large-scale manufacturing processes. Gilead has established a dedicated AI and data science hub in Foster City, which is focused on developing machine learning algorithms to analyze large-scale biological datasets, identify novel drug targets, and optimize the design of clinical trials.

Visa Inc. competitive advantage: Visa's moat is a three-sided network effect. Consumers use Visa because merchants accept it, merchants accept Visa because consumers carry it, and banks issue Visa credentials because both sides already participate. The company also has fraud data, global rules, brand trust, dispute standards, token infrastructure, and bank relationships built across decades. A competitor cannot simply copy the software; it must replicate acceptance, trust, governance, settlement, security, and incentives across the world.

Future prospects matter as much as current results. The growth strategies below explain how Gilead Sciences, Inc. and Visa Inc. each plan to expand from here.

Gilead Sciences, Inc. growth strategy: Gilead's growth strategy centers on extending its HIV leadership with long-acting lenacapavir, defending Biktarvy through lifecycle evidence, expanding liver-disease medicines, and scaling oncology through Trodelvy and Kite cell therapies. CEO Daniel P. O'Day is balancing R&D investment, business development, manufacturing capacity, and shareholder returns as the company prepares for future HIV patent expirations and continued pricing scrutiny. The FY2025 results give Gilead a larger earnings base than the prior file suggested, but the strategic question remains whether next-generation HIV prevention and oncology can offset eventual pressure on legacy antivirals.

Visa Inc. growth strategy: Visa's growth strategy is to expand credentials, increase digital acceptance, grow cross-border and e-commerce volume, sell more value-added services, scale Visa Direct, support tap-to-pay and tokenized commerce, and embed Visa capabilities inside fintech and banking platforms. The company is also buying or partnering for capabilities that make it useful in account-to-account, real-time, and open-banking environments.

A closer look at the financial trajectory of Gilead Sciences, Inc. and Visa Inc. rounds out the comparison.

Gilead Sciences, Inc.: Gilead reported $29.44 billion in FY2025 total revenue and $8.51 billion in net income. Total full-year product sales were $28.9 billion, with HIV product sales rising to $20.8 billion and Biktarvy sales reaching $14.3 billion. Liver Disease product sales were $3.2 billion, Cell Therapy product sales were $1.8 billion, Trodelvy sales were $1.4 billion, and Veklury fell to $911 million. R&D expense was $5.8 billion, operating income was $10.02 billion, and the company ended the year with approximately 17,000 employees. The financial story is a mature HIV cash engine funding long-acting HIV prevention, oncology, and cell therapy while management works through patent-cliff and pricing pressure.

Visa Inc.: Visa reported USD 40.0 billion in fiscal 2025 net revenue, up 11% from fiscal 2024. Net income was USD 20.1 billion and operating expenses were USD 16.0 billion on a GAAP basis. The company processed 257.5 billion transactions on Visa's network and reported USD 14.2 trillion of payments volume in its annual report highlights. This combination of massive volume and low marginal processing cost explains Visa's unusually high profitability.